<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    Radius Health, Inc.

    Radius Health, Inc.

    Radius is a science-driven fully integrated biopharmaceutical company that is comm...

    Radius is a science-driven fully integrated bio...

    Filing Type:    PU
    Sorrento Therapeutics, Inc.

    Sorrento Therapeutics, Inc.

    Sorrento’s lead programs with short-term milestones consist of two clinical stag...

    Sorrento’s lead programs with short-term mile...

    Filing Type:    PU
    ENDRA Life Sciences Inc.

    ENDRA Life Sciences Inc.

    ENDRA Life Sciences' mission is to bring new capabilities to ultrasound and broade...

    ENDRA Life Sciences' mission is to bring new ca...

    Filing Type:    PU
    Abeona Therapeutics, Inc.

    Abeona Therapeutics, Inc.

    Abeona Therapeutics is focused on developing and delivering gene therapy products ...

    Abeona Therapeutics is focused on developing an...

    Filing Type:    PU
    Cidara Therapeutics, Inc.

    Cidara Therapeutics, Inc.

    Cidara is a clinical-stage biotechnology company focused on the discovery, develop...

    Cidara is a clinical-stage biotechnology compan...

    Filing Type:    PU
    Wuxi Biologics (Cayman) Inc

    Wuxi Biologics (Cayman) Inc

    WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading glo...

    WuXi Biologics (stock code: 2269.HK), a Hong Ko...

    Filing Type:    PU
    Autolus Therapeutics plc

    Autolus Therapeutics plc

    Autolus is a clinical-stage, biopharmaceutical company, focused on the development...

    Autolus is a clinical-stage, biopharmaceutical ...

    Filing Type:    PU
    Equillium, Inc.

    Equillium, Inc.

    Equillium is a biotechnology company leveraging deep understanding of immunobiolog...

    Equillium is a biotechnology company leveraging...

    Filing Type:    PU
    Inovio Pharmaceuticals, Inc.

    Inovio Pharmaceuticals, Inc.

    Inovio is bringing IMMUNO-INGENUITY™ to life and is reshaping the future of trea...

    Inovio is bringing IMMUNO-INGENUITY™ to life ...

    Filing Type:    PU
    Neon Therapeutics, Inc.

    Neon Therapeutics, Inc.

    Neon Therapeutics is a clinical-stage immuno-oncology company leading in the field...

    Neon Therapeutics is a clinical-stage immuno-on...

    Filing Type:    PU
    Magenta Therapeutics, Inc.

    Magenta Therapeutics, Inc.

    Magenta Therapeutics is a clinical-stage biotechnology company developing therapeu...

    Magenta Therapeutics is a clinical-stage biotec...

    Filing Type:    PU
    Geron Corporation

    Geron Corporation

    Geron is a late-stage clinical biopharmaceutical company focused on the developmen...

    Geron is a late-stage clinical biopharmaceutica...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.